AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10202683 — intervention group
Group type: COMPARATOR
Intervention: Beta-lactam (ceftazidime or sulbactam/cefoperazone)
Number of subjects: 148
Study 8694724 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.5% ketorolac tromethamine
Number of subjects: 15
Study 8694724 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.1% diclofenac sodium
Number of subjects: 15
Study 8694724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8694724 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ketorolac and diclofenac
Number of subjects: 15
Study 1723467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine, 20 mg b.i.d.
Number of subjects: 3
Study 1723467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine, 20 mg once daily
Number of subjects: 3
Study 1723467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 1723467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 3
Study 1723467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 3
Study 540459 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 540459 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 0
Study 31851556 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) in combination with intensive induction and consolidation therapy
Number of subjects: 588
Study 31851556 — intervention group
Group type: COMPARATOR
Intervention: Standard arm (idarubicin, cytarabine, etoposide, and all-trans-retinoic acid without GO)
Number of subjects: 588
Study 31851556 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 588
Study 31851556 — intervention group
Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 588
Study 31301329 — intervention group
Group type: EXPERIMENTAL
Intervention: BPKs washed with water and detergent after each use and further steam decontamination within a microwavable bag (Study group, N=21)
Number of subjects: 47
Study 31301329 — intervention group
Group type: COMPARATOR
Intervention: Washing, rinsing and drying only (Control group, N=26)
Number of subjects: 47
Study 27549602 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based skin cancer prevention intervention
Number of subjects: 443
Study 27549602 — intervention group
Group type: COMPARATOR
Intervention: Control group (teen alcohol prevention website)
Number of subjects: 443
Study 26727762 — intervention group
Group type: COMPARATOR
Intervention: HDM-SCIT
Number of subjects: 48
Study 26727762 — intervention group
Group type: COMPARATOR
Intervention: HDM-SLIT
Number of subjects: 48
Study 23677021 — intervention group
Group type: EXPERIMENTAL
Intervention: User-filled paper applicator
Number of subjects: 25
Study 23677021 — intervention group
Group type: COMPARATOR
Intervention: Prefilled plastic applicator
Number of subjects: 25
Study 21346613 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment (up to 12 weeks)
Number of subjects: 0
Study 21346613 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 0
Study 19189775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep group (N=26)
Number of subjects: 53
Study 19189775 — intervention group
Group type: COMPARATOR
Intervention: Wake group (N=27)
Number of subjects: 53
Study 17101560 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK plasma levels measurement
Number of subjects: 44
Study 17101560 — intervention group
Group type: EXPERIMENTAL
Intervention: DBI expression measurement
Number of subjects: 44
Study 17101560 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK/DBI ratio measurement
Number of subjects: 44
Study 14751955 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia (15% FIO(2))
Number of subjects: 8
Study 14751955 — intervention group
Group type: COMPARATOR
Intervention: Normobaric normoxia
Number of subjects: 8
Study 11506099 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaraminol infusion starting at 0.25 mg/min
Number of subjects: 50
Study 11506099 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine infusion starting at 5 mg/min
Number of subjects: 50
Study 11506099 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 9402565 — intervention group
Group type: EXPERIMENTAL
Intervention: Protonics knee brace at resistance level 9
Number of subjects: 19
Study 9402565 — intervention group
Group type: EXPERIMENTAL
Intervention: Protonics knee brace at resistance level 6
Number of subjects: 19
Study 9402565 — intervention group
Group type: COMPARATOR
Intervention: Protonics knee brace at resistance levels 6 and 2 with flexion module
Number of subjects: 19
Study 8430233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 0
Study 8430233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2892895 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20
Study 2892895 — intervention group
Group type: EXPERIMENTAL
Intervention: Indenolol
Number of subjects: 20
Study 28856661 — intervention group
Group type: EXPERIMENTAL
Intervention: Silk garments for the treatment of eczema
Number of subjects: 18
Study 27271870 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed mental practice (20 min of MP occurring three times/day)
Number of subjects: 27
Study 27271870 — intervention group
Group type: COMPARATOR
Intervention: Massed mental practice (60 min of MP during a single daily session)
Number of subjects: 27
Study 24385079 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (dose A: 3 injections of 2 U in 0.05 mL of normal saline per injection)
Number of subjects: 58
Study 24385079 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (dose B: 3 injections of 4 U in 0.05 mL of normal saline per injection)
Number of subjects: 58
Study 24385079 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (both doses)
Number of subjects: 58
Study 23607773 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 45
Study 23607773 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TrA)
Number of subjects: 45
Study 23607773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 20521988 — intervention group
Group type: EXPERIMENTAL
Intervention: vanilla soy milk (n = 16)
Number of subjects: 32
Study 20521988 — intervention group
Group type: COMPARATOR
Intervention: reduced-fat dairy milk (n = 16)
Number of subjects: 32
Study 17499863 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 110
Study 17499863 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 110
Study 16182833 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 205
Study 16182833 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine microemulsion (CsA‐ME)
Number of subjects: 205
Study 12861072 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to native Mandarin Chinese speakers in 12 laboratory sessions
Number of subjects: 9
Study 12861072 — intervention group
Group type: COMPARATOR
Intervention: Exposure to recorded Mandarin (audiovisual or audio-only)
Number of subjects: 9
Study 10386821 — intervention group
Group type: EXPERIMENTAL
Intervention: T enanthate (100 mg IM, weekly) + LNG 125 microg by mouth, daily
Number of subjects: 72
Study 10386821 — intervention group
Group type: EXPERIMENTAL
Intervention: T enanthate (100 mg IM, weekly) + LNG 250 microg by mouth, daily
Number of subjects: 72
Study 10386821 — intervention group
Group type: EXPERIMENTAL
Intervention: T enanthate (100 mg IM, weekly) + LNG 500 microg by mouth, daily
Number of subjects: 72
Study 10386821 — intervention group
Group type: COMPARATOR
Intervention: T enanthate (100 mg IM, weekly) + Placebo LNG
Number of subjects: 72
Study 10386821 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (LNG 0, 125, 250, 500)
Number of subjects: 72
Study 8767366 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactovegetarian diet
Number of subjects: 302
Study 8767366 — intervention group
Group type: COMPARATOR
Intervention: Conventional omnivorous diet
Number of subjects: 302
Study 1505563 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 20 mg b.i.d.
Number of subjects: 20
Study 1505563 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg b.i.d. and 20 mg b.i.d. combined
Number of subjects: 20
Study 6360754 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIG (0.5 ml at birth, three months, and six months)
Number of subjects: 185
Study 6360754 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIG (1.0 ml at birth only)
Number of subjects: 185
Study 6360754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 31925605 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Matters intervention
Number of subjects: 143
Study 31925605 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention control group
Number of subjects: 143
Study 31101097 — intervention group
Group type: EXPERIMENTAL
Intervention: Bouldering psychotherapy (BPT)
Number of subjects: 240
Study 31101097 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 240
Study 31101097 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise program (EP)
Number of subjects: 240
Study 27887806 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping and communication‐enhancing intervention (CCI)
Number of subjects: 352
Study 27887806 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 352
Study 27887806 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 352
Study 26313450 — intervention group
Group type: EXPERIMENTAL
Intervention: ranirestat 40 mg/day
Number of subjects: 800
Study 26313450 — intervention group
Group type: EXPERIMENTAL
Intervention: ranirestat 80 mg/day
Number of subjects: 800
Study 26313450 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 800
Study 26313450 — intervention group
Group type: EXPERIMENTAL
Intervention: ranirestat (combined groups)
Number of subjects: 800
Study 23962673 — intervention group
Group type: EXPERIMENTAL
Intervention: Process narratives
Number of subjects: 300
Study 23962673 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience narratives
Number of subjects: 300
Study 23962673 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no stories)
Number of subjects: 300
Study 21420107 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser acupuncture
Number of subjects: 31
Study 21420107 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with red light and skin contact
Number of subjects: 31
Study 21420107 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with red light without skin contact
Number of subjects: 31
Study 19125214 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS over the cerebellum
Number of subjects: 15
Study 19125214 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 15
Study 16421366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir DF, emtricitabine, and efavirenz
Number of subjects: 517
Study 16421366 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine, lamivudine, and efavirenz
Number of subjects: 517
Study 14765577 — intervention group
Group type: EXPERIMENTAL
Intervention: English version of the Kuwait University Anxiety Scale
Number of subjects: 74
Study 14765577 — intervention group
Group type: COMPARATOR
Intervention: Arabic version of the Kuwait University Anxiety Scale
Number of subjects: 74
Study 10642965 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily membrane sweeping (group II)
Number of subjects: 182
Study 10642965 — intervention group
Group type: COMPARATOR
Intervention: Daily dinoprostone (Cervidil) vaginal inserts (group I)
Number of subjects: 182
Study 9032861 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife radiosurgery with marginal dose of 25-30 Gy
Number of subjects: 130
Study 1505293 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (1 mg/kg/day)
Number of subjects: 10
Study 6429876 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (20 mg) and ethinylestradiol (0.04 mg)
Number of subjects: 25
Study 6429876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 6429876 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (NET-AC) and ethinylestradiol (EE2) in an open trial
Number of subjects: 25
Study 6429876 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate (NET-AC) and ethinylestradiol (EE2)
Number of subjects: 25
Study 30809971 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot water extract of Curcuma longa (WEC)
Number of subjects: 47
Study 30809971 — intervention group
Group type: EXPERIMENTAL
Intervention: WEC + curcumin
Number of subjects: 47
Study 30809971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 30809971 — intervention group
Group type: EXPERIMENTAL
Intervention: WEC
Number of subjects: 47
Study 30809971 — intervention group
Group type: COMPARATOR
Intervention: WEC, WEC + curcumin, Placebo
Number of subjects: 47
Study 30035582 — intervention group
Group type: EXPERIMENTAL
Intervention: #Tamojunto intervention (12 weekly classes)
Number of subjects: 6391
Study 30035582 — intervention group
Group type: COMPARATOR
Intervention: Control (no prevention program)
Number of subjects: 6391
Study 29231296 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-min penetration moxibustion
Number of subjects: 60
Study 29231296 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min penetration moxibustion
Number of subjects: 60
Study 27128613 — intervention group
Group type: EXPERIMENTAL
Intervention: MF/F‐MDI (mometasone furoate 800 µg and formoterol fumarate 20 µg)
Number of subjects: 12
Study 27128613 — intervention group
Group type: COMPARATOR
Intervention: MF‐DPI (mometasone furoate 800 µg)
Number of subjects: 12
Study 22349525 — intervention group
Group type: EXPERIMENTAL
Intervention: Infanrix™ hexa (DTPa‐HBV‐IPV/Hib)
Number of subjects: 702
Study 19617580 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational interventions
Number of subjects: 0
Study 19617580 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific factors (e.g., patient expectations, therapeutic alliances)
Number of subjects: 0
Study 19617580 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational nursing interventions
Number of subjects: 0
Study 18288274 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump surgery
Number of subjects: 34
Study 18288274 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 34
Study 16271551 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually fitted shoe inserts
Number of subjects: 33
Study 16271551 — intervention group
Group type: COMPARATOR
Intervention: No correction of LLD (Control)
Number of subjects: 33
Study 11864860 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meals fortified with ferrous fumarate
Number of subjects: 0
Study 11864860 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meals fortified with ferrous sulfate
Number of subjects: 0
Study 11864860 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meals fortified with NaFeEDTA
Number of subjects: 0
Study 10357501 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery revascularization (either bypass surgery or angioplasty)
Number of subjects: 620
Study 10357501 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 620
Study 8584996 — intervention group
Group type: EXPERIMENTAL
Intervention: FXIII from plasma
Number of subjects: 13
Study 8584996 — intervention group
Group type: COMPARATOR
Intervention: FXIII from placenta
Number of subjects: 13
Study 2338028 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-lacquered tablet (M 250 mg, P 25 mg, S 500 mg)
Number of subjects: 6
Study 2338028 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacquered tablets (M 125 mg, P 12.5 mg, S 250 mg)
Number of subjects: 6
Study 2338028 — intervention group
Group type: COMPARATOR
Intervention: Comparison with previously published data
Number of subjects: 6
Study 389420 — intervention group
Group type: EXPERIMENTAL
Intervention: Training plus verapamil
Number of subjects: 40
Study 389420 — intervention group
Group type: COMPARATOR
Intervention: Training plus placebo
Number of subjects: 40
Study 31349850 — intervention group
Group type: EXPERIMENTAL
Intervention: ProLife programme (Motivational Interviewing counselling sessions followed by SMS messages)
Number of subjects: 696
Study 28444456 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation (3.0 g/day post-training)
Number of subjects: 20
Study 28444456 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cornstarch)
Number of subjects: 20
Study 26184302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal breakfast (118 or 236 kcal)
Number of subjects: 24
Study 26184302 — intervention group
Group type: COMPARATOR
Intervention: No breakfast
Number of subjects: 24
Study 23615317 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 7002
Study 23615317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7002
Study 21719599 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD standard risk (MRD-SR) - negative at day 33 and day 78
Number of subjects: 464
Study 21719599 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD intermediate risk (MRD-IR) - positive at day 33 or 78 and < 10(-3) at day 78
Number of subjects: 464
Study 21719599 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD high risk (MRD-HR) - ≥ 10(-3) at day 78
Number of subjects: 464
Study 21719599 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD negative at TP2
Number of subjects: 464
Study 21719599 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD ≥ 10(-3) at TP2
Number of subjects: 464
Study 19700947 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (mean dose: 5.7 ± 0.9 mg/day)
Number of subjects: 22
Study 19700947 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mean dose: 5.6 ± 1.2 mg/day)
Number of subjects: 22
Study 16918615 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 microg/cm2 (2 p.p.m.) of MCI/MI/unit area of the skin for 4 weeks
Number of subjects: 35
Study 16918615 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.094 microg/cm2 (7.5 p.p.m.) of MCI/MI/unit area of the skin for 4 weeks
Number of subjects: 35
Study 16918615 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not specified)
Number of subjects: 35
Study 12163794 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation (1-4 mg x kg(‐1) x hr(‐1))
Number of subjects: 20
Study 10023893 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured interdisciplinary assessment with referral to relevant services (n=184)
Number of subjects: 397
Study 10023893 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (n=213)
Number of subjects: 397
Study 7772482 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin
Number of subjects: 0
Study 7772482 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate
Number of subjects: 0
Study 7772482 — intervention group
Group type: COMPARATOR
Intervention: Inert gel base
Number of subjects: 0
Study 2185611 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized administration of SMAST‐13
Number of subjects: 280
Study 2185611 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil administration of SMAST‐13
Number of subjects: 280
Study 2185611 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized administration of CAGE
Number of subjects: 280
Study 2185611 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil administration of CAGE
Number of subjects: 280
Study 2185611 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized administration of quantity-frequency scale
Number of subjects: 280
Study 2185611 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil administration of quantity-frequency scale
Number of subjects: 280
Study 378509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticrynafen (TCN) 125 mg daily
Number of subjects: 9
Study 378509 — intervention group
Group type: COMPARATOR
Intervention: Probenecid (PBC) 500 or 1,000 mg daily
Number of subjects: 9
Study 378509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticrynafen (TCN)
Number of subjects: 9
Study 30010923 — intervention group
Group type: EXPERIMENTAL
Intervention: FBT incorporating AAT strategies (FBT-AAT)
Number of subjects: 84
Study 30010923 — intervention group
Group type: COMPARATOR
Intervention: FBT
Number of subjects: 84
Study 27692638 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin extended-release 20-mg once-daily
Number of subjects: 36
Study 27692638 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin extended-release under fed conditions
Number of subjects: 36
Study 27692638 — intervention group
Group type: COMPARATOR
Intervention: Lorcaserin extended-release under fasted conditions
Number of subjects: 36
Study 27692638 — intervention group
Group type: COMPARATOR
Intervention: Lorcaserin immediate-release 10-mg BID
Number of subjects: 36
Study 25642918 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs treatment
Number of subjects: 290
Study 25642918 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of neuroendocrine factors, clinical characteristics, and gene polymorphisms
Number of subjects: 290
Study 23998714 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT (Cardiac-resynchronization therapy)
Number of subjects: 809
Study 23998714 — intervention group
Group type: COMPARATOR
Intervention: Control (CRT capability turned off)
Number of subjects: 809
Study 23998714 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT
Number of subjects: 809
Study 23998714 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 809
Study 20381665 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 20381665 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 18218291 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox without dispersion
Number of subjects: 28
Study 18218291 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox dispersed in orange juice
Number of subjects: 28